SK286245B6 - Farmaceutická kompozícia obsahujúca ziprasidon a spôsob výroby veľkých kryštálov monohydrátu hydrochloridu ziprasidonu - Google Patents

Farmaceutická kompozícia obsahujúca ziprasidon a spôsob výroby veľkých kryštálov monohydrátu hydrochloridu ziprasidonu Download PDF

Info

Publication number
SK286245B6
SK286245B6 SK769-99A SK76999A SK286245B6 SK 286245 B6 SK286245 B6 SK 286245B6 SK 76999 A SK76999 A SK 76999A SK 286245 B6 SK286245 B6 SK 286245B6
Authority
SK
Slovakia
Prior art keywords
composition
ziprasidone
particle size
mean
free base
Prior art date
Application number
SK769-99A
Other languages
English (en)
Slovak (sk)
Other versions
SK76999A3 (en
Inventor
Frank Robert Busch
Angela Carol Gatlin Hausberger
Bijan Rasadi
Daniel Ray Arenson
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22216447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK286245(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of SK76999A3 publication Critical patent/SK76999A3/sk
Publication of SK286245B6 publication Critical patent/SK286245B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Detergent Compositions (AREA)
  • Feeding Of Articles By Means Other Than Belts Or Rollers (AREA)
  • Polyamides (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
SK769-99A 1998-06-15 1999-06-09 Farmaceutická kompozícia obsahujúca ziprasidon a spôsob výroby veľkých kryštálov monohydrátu hydrochloridu ziprasidonu SK286245B6 (sk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8922998P 1998-06-15 1998-06-15

Publications (2)

Publication Number Publication Date
SK76999A3 SK76999A3 (en) 2000-12-11
SK286245B6 true SK286245B6 (sk) 2008-06-06

Family

ID=22216447

Family Applications (1)

Application Number Title Priority Date Filing Date
SK769-99A SK286245B6 (sk) 1998-06-15 1999-06-09 Farmaceutická kompozícia obsahujúca ziprasidon a spôsob výroby veľkých kryštálov monohydrátu hydrochloridu ziprasidonu

Country Status (45)

Country Link
US (1) US6150366A (bg)
EP (1) EP0965343B1 (bg)
JP (2) JP3441676B2 (bg)
KR (1) KR100338915B1 (bg)
CN (1) CN1307994C (bg)
AP (1) AP1216A (bg)
AR (1) AR015553A1 (bg)
AT (1) ATE240732T1 (bg)
AU (1) AU753820B2 (bg)
BG (1) BG64691B1 (bg)
BR (1) BR9902268A (bg)
CA (1) CA2274338C (bg)
CO (1) CO5070579A1 (bg)
CY (1) CY2003002I1 (bg)
CZ (1) CZ297954B6 (bg)
DE (1) DE69908021T2 (bg)
DK (1) DK0965343T3 (bg)
EA (1) EA002223B1 (bg)
ES (1) ES2197581T3 (bg)
GT (1) GT199900080A (bg)
HK (1) HK1024184A1 (bg)
HN (1) HN1999000089A (bg)
HR (1) HRP990193B1 (bg)
HU (1) HU226487B1 (bg)
ID (1) ID23546A (bg)
IL (1) IL130424A (bg)
IS (1) IS2182B (bg)
MA (1) MA26647A1 (bg)
MY (1) MY121397A (bg)
NO (1) NO316713B1 (bg)
NZ (1) NZ336271A (bg)
OA (1) OA11064A (bg)
PA (1) PA8475601A1 (bg)
PE (1) PE20000632A1 (bg)
PL (2) PL195209B1 (bg)
PT (1) PT965343E (bg)
RS (1) RS49611B (bg)
SG (1) SG77243A1 (bg)
SI (1) SI0965343T1 (bg)
SK (1) SK286245B6 (bg)
TR (1) TR199901379A2 (bg)
TW (1) TW590774B (bg)
UA (1) UA59383C2 (bg)
UY (1) UY25649A1 (bg)
ZA (1) ZA993938B (bg)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US7175855B1 (en) * 1999-05-27 2007-02-13 Pfizer Inc. Ziprasidone suspension
ES2191618T3 (es) * 1999-05-27 2003-09-16 Pfizer Prod Inc Suspension de ziprasidona.
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
KR101476574B1 (ko) 1999-10-29 2014-12-24 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
MXPA03003895A (es) 2000-10-30 2003-07-28 Euro Celtique Sa Formulaciones de hidrocodona de liberacion controlada.
UY27668A1 (es) * 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
EP2301537A1 (en) * 2002-05-17 2011-03-30 Duke University Zonisamide for the treatment of obesity
US7488729B2 (en) * 2002-12-04 2009-02-10 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride salt and process for preparation thereof
WO2004050655A1 (en) * 2002-12-04 2004-06-17 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride
US20050143396A1 (en) * 2003-04-11 2005-06-30 Hertero Drugs Limited Novel crystalline forms of ziprasidone hydrochloride
SI2316456T1 (sl) * 2003-04-29 2017-10-30 Orexigen Therapeutics, Inc. Sestavki za vplivanje na izgubo teže, ki obsegajo opioidni antagonist in bupropion
EP1530570A2 (en) * 2003-06-03 2005-05-18 Teva Pharmaceutical Industries Limited CRISTALLINE ZIPRASIDONE HCl AND PROCESSES FOR PREPARATION THEREOF
US20050049295A1 (en) * 2003-06-12 2005-03-03 Dr. Reddy's Laboratories Limited Process for the preparation of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1piperazinyl) ethyl)-6-chloro-1, 3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride) and its intermediate
KR20090080143A (ko) * 2003-09-02 2009-07-23 화이자 프로덕츠 인크. 지프라시돈의 지속 방출형 투여 형태
EP1628973A2 (en) * 2003-10-24 2006-03-01 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
EP1687300A4 (en) * 2003-11-28 2007-08-01 Wockhardt Ltd PROCESS FOR THE PREPARATION OF ZIPRASIDONE MONOHYDROCHLORIDE HYDRATE
CN1934108A (zh) 2003-12-18 2007-03-21 特瓦制药工业有限公司 齐拉西酮碱的多晶型b2
US20050163858A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Ziprasidone formulations
WO2005070461A2 (en) * 2004-01-13 2005-08-04 Duke University Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
PT1720867E (pt) * 2004-02-27 2010-01-28 Ranbaxy Lab Ltd Processo para a preparação de ziprasidona
CN1968692A (zh) * 2004-05-03 2007-05-23 杜克大学 影响体重减轻的组合物
WO2005107719A2 (en) * 2004-05-06 2005-11-17 Sandoz Ag Pharmaceutical composition comprising hydrophobic drug having improved solubility
CA2467538C (en) * 2004-05-14 2010-08-24 Apotex Pharmachem Inc. New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
WO2005123086A2 (en) * 2004-06-11 2005-12-29 Dr. Reddy's Laboratories Ltd. Ziprasidone dosage form
CA2471219A1 (en) * 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
US9044503B2 (en) * 2004-08-27 2015-06-02 University Of Kentucky Research Foundation Amyloid peptide inactivating enzyme to treat alzheimer's disease peripherally
RU2007106036A (ru) 2004-08-31 2008-10-10 Пфайзер Продактс Инк. (Us) Антитело к cd40: препарат и способы
CA2587710C (en) * 2004-11-16 2014-10-21 Elan Pharma International Ltd. Injectable nanoparticulate olanzapine formulations
WO2006085168A2 (en) * 2005-01-07 2006-08-17 Ranbaxy Laboratories Limited Solid oral dosage forms of ziprasidone containing colloidal silicone dioxide
US7749529B2 (en) * 2005-02-08 2010-07-06 Ash Access Technology, Inc. Catheter lock solution comprising citrate and a paraben
EP1863806A1 (en) * 2005-02-11 2007-12-12 Teva Pharmaceutical Industries Ltd Amorphous ziprasidone mesylate
ITMI20050346A1 (it) 2005-03-07 2006-09-08 Dipharma Spa Forma solida di ziprasidone cloridrato
CA2500667C (en) * 2005-03-11 2013-01-15 Apotex Pharmachem Inc. Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions
US20060270684A1 (en) * 2005-03-14 2006-11-30 Judith Aronhime Crystalline forms of ziprasidone mesylate
WO2006099452A1 (en) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Anhydrous ziprasidone mesylate and a process for its preparation
US20080305161A1 (en) * 2005-04-13 2008-12-11 Pfizer Inc Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
US20080193542A1 (en) * 2005-04-13 2008-08-14 Pfizer Inc. Injectable Deopot Formulations and Methods For Providing Sustained Release of Nanoparticle Compositions
BRPI0610028A2 (pt) * 2005-04-22 2010-05-18 Wyeth Corp combinações terapêuticas para o tratamento ou a prevenção de distúrbios psicóticos
BR122020005056B1 (pt) 2005-05-26 2023-01-10 Sumitomo Pharma Co., Ltd Método para preparar uma preparação oral que compreende cloridrato de n-[4-[4-(1,2- benziso-tiazol-3-il)-1-piperazinil]-(2r,3r)-2,3-tetrametileno-butil]-(1r,2s,3r,4s)-2,3-biciclo[2,2,1] heptanodicarboxiimida (lurasidona)
EP1901722A4 (en) * 2005-06-20 2011-06-15 Elan Pharma Int Ltd NANOTEHOUS COMPOSITIONS WITH CONTROLLED RELEASE FROM ARYL-HETEROCYCLIC COMPOUNDS
JP2008546781A (ja) * 2005-06-20 2008-12-25 エラン・ファルマ・インターナショナル・リミテッド アリール−複素環式化合物を含んでなるナノ粒状及び制御放出の組成物
EP2135603B1 (en) 2005-11-22 2013-01-02 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
PT1954241E (pt) * 2005-11-28 2012-06-01 Orexigen Therapeutics Inc Formulação de zonisamida de libertação sustentada
PL379569A1 (pl) * 2006-04-28 2007-10-29 Pliva Kraków Zakłady Farmaceutyczne Spółka Akcyjna Sposób wytwarzania kompozycji farmaceutycznej zawierającej substancję aktywną ziprasidone lub jego farmaceutycznie dopuszczalną sól zwiększający rozpuszczalność i biodostępność tego leku, kompozycja farmaceutyczna i zastosowanie hydrofilowych substancji pomocniczych
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
EP1892243A1 (en) * 2006-08-02 2008-02-27 KRKA, tovarna zdravil, d.d., Novo mesto Polymorphic forms of ziprasidone sulphate salts
EP1889844A3 (en) * 2006-08-02 2008-03-05 Krka Polymorphic forms of ziprasidone sulphates
KR101735466B1 (ko) 2006-11-09 2017-05-15 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
KR20150082689A (ko) 2006-11-09 2015-07-15 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
AU2008254957A1 (en) * 2007-05-18 2008-11-27 Scidose Llc Ziprasidone formulations
WO2009032558A2 (en) * 2007-08-31 2009-03-12 Dr. Reddy's Laboratories Ltd. Preparation of ziprasidone hydrochloride monohydrate
US8410268B2 (en) * 2008-03-11 2013-04-02 Alkem Laboratories Limited Process for the preparation of ziprasidone
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
DE102008045854A1 (de) 2008-09-05 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Partikel aus Ziprasidone und einem Sprengmittel enthaltende Pharmazeutische Zusammensetzung
US8686009B2 (en) 2009-06-25 2014-04-01 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds
EP2340834A1 (en) 2009-12-30 2011-07-06 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Enhanced Solubility of Ziprasidone
CN102724878A (zh) 2010-01-11 2012-10-10 奥雷西根治疗公司 在重度抑郁症患者中提供体重减轻疗法的方法
EP3251660B1 (en) 2010-02-25 2019-10-16 Bristol-Myers Squibb Holdings Ireland Unlimited Company Apixaban formulations
WO2011148253A2 (en) 2010-05-25 2011-12-01 Aurobindo Pharma Limited Solid dosage forms of antipsychotics
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
DK3730132T3 (da) 2012-06-06 2022-08-08 Nalpropion Pharmaceuticals Llc Sammensætning til anvendelse ved en fremgangsmåde til behandling af overvægt og obesitas hos patienter med høj kardiovaskulær risiko
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
EP3761983A1 (en) 2018-03-05 2021-01-13 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264446A (en) * 1980-09-09 1993-11-23 Bayer Aktiengesellschaft Solid medicament formulations containing nifedipine, and processes for their preparation
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US4883795A (en) * 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
DE4141268A1 (de) * 1991-12-14 1993-06-17 Merck Patent Gmbh Pharmazeutische zubereitung
US5338846A (en) * 1992-08-26 1994-08-16 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5359068A (en) * 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
ES2210450T3 (es) * 1996-02-13 2004-07-01 Pfizer Inc. Profarmacos de 5-(2-(4-(1,2-benzoisotiazol-3-il)-1-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona.
DK0901786T3 (da) * 1997-08-11 2007-10-08 Pfizer Prod Inc Faste farmaceutiske dispersioner med foröget biotilgængelighed

Also Published As

Publication number Publication date
OA11064A (en) 2002-03-13
ES2197581T3 (es) 2004-01-01
JP2000007566A (ja) 2000-01-11
HRP990193B1 (en) 2003-08-31
CZ297954B6 (cs) 2007-05-09
CA2274338C (en) 2003-04-15
HUP9901960A2 (hu) 2000-08-28
MY121397A (en) 2006-01-28
AR015553A1 (es) 2001-05-02
JP4187423B2 (ja) 2008-11-26
SK76999A3 (en) 2000-12-11
JP3441676B2 (ja) 2003-09-02
DE69908021D1 (de) 2003-06-26
HN1999000089A (es) 1999-11-03
PL195209B1 (pl) 2007-08-31
ID23546A (id) 2000-05-04
PT965343E (pt) 2003-08-29
DK0965343T3 (da) 2003-08-04
NO992892L (no) 1999-12-16
HU9901960D0 (en) 1999-08-30
HK1024184A1 (en) 2000-10-05
KR100338915B1 (ko) 2002-05-30
EP0965343A3 (en) 2000-02-23
HRP990193A2 (en) 2000-02-29
UY25649A1 (es) 2000-02-23
BG103489A (bg) 2000-07-31
IL130424A (en) 2003-10-31
NZ336271A (en) 2000-10-27
CN1242987A (zh) 2000-02-02
US6150366A (en) 2000-11-21
HUP9901960A3 (en) 2000-09-28
CZ212799A3 (cs) 2000-09-13
TW590774B (en) 2004-06-11
BR9902268A (pt) 2000-05-02
AU753820B2 (en) 2002-10-31
RS49611B (sr) 2007-06-04
JP2002003492A (ja) 2002-01-09
CO5070579A1 (es) 2001-08-28
CA2274338A1 (en) 1999-12-15
SI0965343T1 (en) 2003-10-31
EP0965343A2 (en) 1999-12-22
EA002223B1 (ru) 2002-02-28
PA8475601A1 (es) 2000-09-29
KR20000006143A (ko) 2000-01-25
HU226487B1 (en) 2009-03-02
IL130424A0 (en) 2000-06-01
NO316713B1 (no) 2004-04-13
CN1307994C (zh) 2007-04-04
ZA993938B (en) 2000-12-14
EA199900467A2 (ru) 1999-12-29
NO992892D0 (no) 1999-06-14
AP9901579A0 (en) 1999-06-30
CY2003002I1 (el) 2009-11-04
AU3398399A (en) 1999-12-23
TR199901379A2 (xx) 2000-01-21
SG77243A1 (en) 2000-12-19
EP0965343B1 (en) 2003-05-21
EA199900467A3 (ru) 2000-04-24
BG64691B1 (bg) 2005-12-30
PE20000632A1 (es) 2000-07-26
ATE240732T1 (de) 2003-06-15
IS2182B (is) 2006-12-15
UA59383C2 (uk) 2003-09-15
MA26647A1 (fr) 2004-12-20
YU27199A (sh) 2002-12-10
DE69908021T2 (de) 2003-11-27
PL333737A1 (en) 1999-12-20
AP1216A (en) 2003-10-19
GT199900080A (es) 2000-11-29
PL195606B1 (pl) 2007-10-31
IS5079A (is) 1999-12-16

Similar Documents

Publication Publication Date Title
SK286245B6 (sk) Farmaceutická kompozícia obsahujúca ziprasidon a spôsob výroby veľkých kryštálov monohydrátu hydrochloridu ziprasidonu
US20200375968A1 (en) Apixaban formulations
EP2623100B1 (en) Preparation for improving solubility of poorly soluble drug
EP1574215B1 (en) Solid drug for oral use
US20130084335A1 (en) Ivabradine-containing pharmaceutical composition
US20100034885A1 (en) Formulations containing glimepiride and/or its salts
US20210401748A1 (en) Powder for oral suspension containing lamotrigine
CN109260207A (zh) 嘧啶二酮衍生物化合物的制剂
US20220323358A1 (en) Powder for oral suspension containing tadalafil
US20220073474A1 (en) Pharmaceutical compound, the method of its making and use as medicinal agent
AU2017228681B2 (en) Apixaban formulations
MXPA99005524A (en) Ziprasid formulations
US20050129768A1 (en) Pharmaceutical formulation containing an LTB4-antagonist, as well as processes for the preparation thereof and the use thereof

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20130609